A Chinese COVID-19 vaccine clinical trial is reporting early results that show 81% of the participants suffered at least one adverse reaction within seven days after vaccination. The trial, developed by CanSino Biologics, uses cell lines from an aborted human fetus, along with a chimpanzee adenovirus vector.
Canada’s National Research Council is also using the human cell line for its COVID-19 vaccine candidates. Adverse reactions reported so far with CanSino’s vaccine range from pain at the injection site to fever, headache, severe fatigue and muscle and joint pain.
SOURCE: The Vaccine Reaction July 6, 2020